Can you take Sacituzumab govitecan with Xbryk?

The denosumab in Xbryk has a major potential interaction with Hypocalcemia.

Preexisting hypocalcemia must be corrected prior to initiating treatment with denosumab. Caution should be exercised in patients predisposed to hypocalcemia and any disturbances of mineral metabolism, such as history of hypoparathyroidism, thyroid or parathyroid surgery, malabsorption syndromes, excision of small intestine, severe renal impairment or dialysis. Clinical monitoring of calcium and mineral levels (phosphorus and magnesium) are highly recommended within 14 days of denosumab injection. It is important to maintain calcium levels with adequate calcium and vitamin D supplementation.

The denosumab in Xbryk has a major potential interaction with Hypoparathyroidism.

Preexisting hypocalcemia must be corrected prior to initiating treatment with denosumab. Caution should be exercised in patients predisposed to hypocalcemia and any disturbances of mineral metabolism, such as history of hypoparathyroidism, thyroid or parathyroid surgery, malabsorption syndromes, excision of small intestine, severe renal impairment or dialysis. Clinical monitoring of calcium and mineral levels (phosphorus and magnesium) are highly recommended within 14 days of denosumab injection. It is important to maintain calcium levels with adequate calcium and vitamin D supplementation.

The denosumab in Xbryk has a moderate potential interaction with Immunodeficiency.

Denosumab should be used with caution in patients with impaired immune systems or taking concomitant immunosuppressant agents as they may be at increased risk for serious infections.

Sacituzumab govitecan has a moderate potential interaction with Liver Disease.

The safety of sacituzumab govitecan has not been established in patients with moderate (total bilirubin greater than 1.5 to 3 times the upper limit of normal [1.5 to 3 x ULN]) or severe (total bilirubin greater than 3 x ULN) liver dysfunction; it has not been tested in patients with AST or ALT greater than 3 x ULN without liver metastases, or AST or ALT greater than 5 x ULN with liver metastases. No recommendations can be made for the starting dosage; caution is advised in patients with moderate or severe liver dysfunction. No adjustment to the starting dosage is needed in patients with mild liver dysfunction.

The denosumab in Xbryk has a major potential interaction with Renal Dysfunction.

Preexisting hypocalcemia must be corrected prior to initiating treatment with denosumab. Caution should be exercised in patients predisposed to hypocalcemia and any disturbances of mineral metabolism, such as history of hypoparathyroidism, thyroid or parathyroid surgery, malabsorption syndromes, excision of small intestine, severe renal impairment or dialysis. Clinical monitoring of calcium and mineral levels (phosphorus and magnesium) are highly recommended within 14 days of denosumab injection. It is important to maintain calcium levels with adequate calcium and vitamin D supplementation.

Sacituzumab govitecan has a moderate potential interaction with Renal Dysfunction.

There are no data on the pharmacokinetics of sacituzumab govitecan in patients with severe renal dysfunction (CrCl 15 to 29 mL/min) or end-stage renal disease (CrCl less than 15 mL/min); caution is recommended in these patients.

The denosumab in Xbryk has a major potential interaction with Thyroid Disease.

Preexisting hypocalcemia must be corrected prior to initiating treatment with denosumab. Caution should be exercised in patients predisposed to hypocalcemia and any disturbances of mineral metabolism, such as history of hypoparathyroidism, thyroid or parathyroid surgery, malabsorption syndromes, excision of small intestine, severe renal impairment or dialysis. Clinical monitoring of calcium and mineral levels (phosphorus and magnesium) are highly recommended within 14 days of denosumab injection. It is important to maintain calcium levels with adequate calcium and vitamin D supplementation.